U.S. Markets closed

CASI Pharmaceuticals, Inc. (CASI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0300-0.0200 (-0.98%)
At close: 4:00PM EDT

CASI Pharmaceuticals, Inc.

9620 Medical Center Drive
Suite 300
Rockville, MD 20850
United States
240 864 2600
http://www.casipharmaceuticals.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees144

Key Executives

NameTitlePayExercisedYear Born
Dr. Wei-Wu HeChairman & CEO810.83kN/A1965
Dr. Wei Zhang Ph.D.Pres506.1kN/A1959
Dr. Alexander A. ZukiwskiChief Medical Officer535.35kN/A1957
Ms. Cynthia Wong HuCOO, Gen. Counsel & Sec.N/AN/A1970
Dr. James E. GoldschmidtSr. VP of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Corporate Governance

CASI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.